INTRA-CELLUAR THER revenue breakdown overview

INTRA-CELLUAR THER revenue for the last year amounted to 618.35 M CHF, the most of which — 618.35 M CHF — came from its highest performing source at the moment, Small Molecule Drugs, the year earlier bringing 390.97 M CHF. The greatest contribution to the revenue figure was made by United States — last year it brought INTRA-CELLUAR THER 618.35 M CHF, and the year before that — 390.97 M CHF.